within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BX02_ArterolaneAndPiperaquine;

model ArterolaneAndPiperaquine_1
  extends Pharmacolibrary.Drugs.ATC.P.P01BX02_1;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>P01BX02_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Arterolane and piperaquine is a fixed-dose combination antimalarial, currently used for the treatment of malaria, particularly in South Asia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for piperaquine in healthy adult volunteers after oral administration of 750 mg piperaquine phosphate plus 150 mg arterolane maleate.</p><h4>References</h4><ol><li><p>Gautam, A, et al., &amp; Paliwal, J (2011). Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. <i>Journal of clinical pharmacology</i> 51(11) 1519–1528. DOI:<a href=&quot;https://doi.org/10.1177/0091270010385578&quot;>10.1177/0091270010385578</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21148048/&quot;>https://pubmed.ncbi.nlm.nih.gov/21148048</a></p></li><li><p>Valecha, N, et al., &amp; Anvikar, AR (2016). Comparison of the safety and efficacy of fixed-dose combination of arterolane maleate and piperaquine phosphate with chloroquine in acute, uncomplicated Plasmodium vivax malaria: a phase III, multicentric, open-label study. <i>Malaria journal</i> 15 42–None. DOI:<a href=&quot;https://doi.org/10.1186/s12936-016-1084-1&quot;>10.1186/s12936-016-1084-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26818020/&quot;>https://pubmed.ncbi.nlm.nih.gov/26818020</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end ArterolaneAndPiperaquine_1;
